Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hexavalent group B streptococcus conjugate vaccine (Juwei Biotech)
- Development stage
- Unknown
- Lead developer
- Suzhou Ju Microbial Technology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Developed by Suzhou Juwei Biological Technology (Juwei Bio), this hexavalent Group B Streptococcus (GBS) conjugate vaccine is designed to prevent invasive GBS infections, which are a leading cause of neonatal sepsis, meningitis, and pneumonia. The vaccine utilizes a polysaccharide conjugate modality, where capsular polysaccharides from six common GBS serotypes (typically Ia, Ib, II, III, IV, and V) are chemically linked to a carrier protein to enhance immunogenicity and induce a T-cell dependent immune response. This approach is intended to provide broad protection against the majority of disease-causing GBS strains globally. The candidate is currently in Phase 1 clinical development, primarily targeting maternal immunization to protect infants through transplacental antibody transfer.
- Other names
- 6价B族链球菌结合疫苗6-valent GBS conjugate vaccinehexavalent GBS polysaccharide conjugate vaccine
02
Targets
GBS CPS (Group B Streptococcus capsular polysaccharide)
Beyond the preview
Go deeper on hexavalent group B streptococcus conjugate vaccine (Juwei Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hexavalent group B streptococcus conjugate vaccine (Juwei Biotech).